Vivos Therapeutics (NASDAQ:VVOS) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Vivos Therapeutics (NASDAQ:VVOS) posted its earnings results on Wednesday. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07), Zacks reports. Vivos Therapeutics had a negative net margin of 121.37% and a negative return on equity of 849.22%.

Vivos Therapeutics Trading Up 0.8%

Shares of Vivos Therapeutics stock traded up $0.00 on Wednesday, reaching $0.59. The company had a trading volume of 265,593 shares, compared to its average volume of 189,360. The firm has a market cap of $8.09 million, a price-to-earnings ratio of -0.29 and a beta of 6.25. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.24 and a quick ratio of 0.24. The firm’s 50-day moving average price is $1.06 and its two-hundred day moving average price is $1.65. Vivos Therapeutics has a 1 year low of $0.57 and a 1 year high of $7.95.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Ascendiant Capital Markets lowered their price objective on shares of Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. HC Wainwright lowered their price objective on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $2.75.

Insider Activity at Vivos Therapeutics

In related news, major shareholder Michael C. Skaff bought 1,353,625 shares of the company’s stock in a transaction dated Tuesday, March 31st. The stock was purchased at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the acquisition, the insider owned 1,353,625 shares in the company, valued at $1,813,857.50. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Vivos Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in shares of Vivos Therapeutics in the 2nd quarter worth approximately $65,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics during the 2nd quarter valued at $220,000. DRW Securities LLC boosted its holdings in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after acquiring an additional 74,441 shares during the period. Finally, Connective Capital Management LLC purchased a new position in Vivos Therapeutics during the 3rd quarter valued at $620,000. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.